
   
   
      
         
            What_WP Is_VBZ Gene_NNP Therapy_NNP ?_.
            

            Two_CD weeks_NNS ago_RB ,_, 18_CD -_: year-old_JJ Jesse_NNP Gelsinger_NNP died_VBD while_IN undergoing_VBG
experimental_JJ gene_NN therapy_NN treatment_NN for_IN a_DT metabolic_JJ disease_NN of_IN the_DT liver_NN ._. The_DT
National_NNP Institutes_NNPS of_IN Health_NNP are_VBP now_RB reviewing_VBG the_DT safety_NN of_IN gene_NN therapy_NN
trials_NNS ._. What_WP is_VBZ gene_NN therapy_NN ?_.

            Genes_NNP are_VBP hereditary_JJ units_NNS that_WDT carry_VBP nature_NN 's_POS blueprints_NNS for_IN making_VBG the_DT
multitude_NN of_IN proteins_NNS that_WDT build_VBP enzymes_NNS and_CC other_JJ body_NN chemicals_NNS to_TO sustain_VB
life_NN ._. Human_JJ beings_NNS have_VBP between_IN 50_CD ,_, 000_CD and_CC 150_CD ,_, 000_CD genes--the_JJ number_NN is_VBZ hotly_RB
debated_VBN among_IN scientists--and_JJ many_JJ diseases_NNS can_MD be_VB linked_VBN to_TO defects_NNS in_IN one_CD or_CC
more_JJR of_IN these_DT genes_NNS ._. There_EX are_VBP inherited_VBN defects_NNS ,_, like_IN those_DT that_WDT cause_VBP cystic_JJ
fibrosis_NNS ,_, and_CC acquired_VBD defects_NNS ,_, like_IN those_DT that_WDT cause_VBP some_DT forms_NNS of_IN cancer_NN ._.
People_NNS who_WP have_VBP genetic-based_JJ diseases_NNS typically_RB take_VBP drugs_NNS that_WDT treat_VBP their_PRP$
symptoms_NNS ,_, not_RB the_DT cause_NN ._.

            It_PRP may_MD take_VB decades_NNS or_CC even_RB centuries_NNS to_TO completely_RB understand_VB the_DT
relationship_NN between_IN genes_NNS and_CC disease_NN ._. But_CC where_WRB the_DT connection_NN is_VBZ understood_VBN ,_,
scientists_NNS are_VBP devising_VBG gene_NN therapies_NNS that_WDT aim_NN to_TO eliminate_VB disease_NN by_IN
introducing_VBG healthy_JJ genes_NNS (_( isolated_VBN and_CC reproduced_VBD in_IN the_DT laboratory_NN )_) to_TO
compensate_VB for_IN the_DT defective_JJ ones_NNS ._.

            One_CD way_NN to_TO deliver_VB healthy_JJ genes_NNS is_VBZ by_IN placing_VBG them_PRP inside_IN a_DT tamed_JJ virus_NN
that_IN in_IN turn_NN can_MD enter_VB the_DT patient_NN 's_POS affected_VBN cells_NNS ._. In_IN Gelsinger_NNP 's_POS case_NN ,_, the_DT
goal_NN was_VBD to_TO introduce_VB therapeutic_JJ genes_NNS into_IN his_PRP$ liver_NN cells_NNS ._. His_PRP$ cause_NN of_IN
death_NN is_VBZ still_RB a_DT mystery_NN :_: One_CD theory_NN is_VBZ that_IN the_DT virus_NN was_VBD still_RB active_JJ and_CC may_MD
have_VB killed_VBD him_PRP ._. This_DT therapeutic_JJ trial_NN has_VBZ been_VBN suspended_VBN pending_VBG an_DT
investigation_NN ._.

            Theoretically_RB ,_, gene_NN therapy_NN could_MD be_VB used_VBN to_TO cure_VB infectious_JJ diseases_NNS like_IN
HIV_NNP by_IN giving_VBG cells_NNS extra_JJ defense_NN mechanisms_NNS ._.

            Though_IN the_DT benefits_NNS of_IN gene_NN therapy_NN are_VBP theoretically_RB large_JJ ,_, none_NN of_IN the_DT
dozens_NNS of_IN trials_NNS in_IN the_DT U_NNP ._. S_NNP ._. (_( or_CC elsewhere_RB )_) has_VBZ achieved_VBN a_DT long-term_JJ cure_NN for_IN
any_DT ailment_NN ._. One_CD obstacle_NN is_VBZ the_DT body_NN 's_POS natural_JJ defense_NN :_: The_DT immune_JJ system_NN
recognizes_VBZ the_DT virus_NN as_IN a_DT threat_NN and_CC attacks_NNS it_PRP ._. Another_DT is_VBZ that_IN the_DT cells_NNS
engineered_VBN by_IN therapy_NN often_RB do_VBP not_RB produce_VB enough_RB of_IN the_DT needed_VBN protein_NN to_TO cure_VB
the_DT disorder_NN ._.

            (_( PBS_NNP offers_VBZ a_DT helpful_JJ animation_NN of_IN one_CD gene_NN therapy_NN preparation_NN ._. Also_RB see_VB the_DT Web_NNP site_NN
of_IN the_DT Human_NNP Genome_NNP
Project_NNP for_IN an_DT exhaustive_JJ look_NN at_IN the_DT world_NN of_IN genomics_NNS ._. )_)

            Next_JJ question_NN ?_.

         
      
   
